Fiche publication
Date publication
septembre 2025
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre
Tous les auteurs :
Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini Piocelle F, Mohty M, Schiano de Colella JM, Macro M, Adiko D, Dib M, Fontan J, Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala JA, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J
Lien Pubmed
Résumé
The prognostic heterogeneity of multiple myeloma is mainly driven by genomic features of myeloma cells. The International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) recently proposed a high-risk (HR) genomic model in order to have a consensus definition of genomic risk. We performed NGS panel in 6528 new diagnosed myeloma patients (NDMM) and 1583 patients at first relapse, between 2019 and 2024. We observed that 22.4% of patients at diagnosis and 36.7% at first relapse were HR according to the Consensus Genomic Staging (CGS). Clinical data were available for 2695 patients at diagnosis. After a median follow-up of 35 months, the median PFS was 30 months for HR NDMM patients, vs 51 months for standard-risk (SR) (p<0.0001). HR cytogenetic criteria from the Revised-ISS score were not able to discriminate patients in HR nor SR IMS/IMWG genomic subgroups. Looking at each criteria independently, we found that the presence of del(17p), TP53 mutation, biallelic del(1p32), or the combination of intermediate risk cytogenetics (gain 1q, del(1p32), t(4;14), t(14;16), t(14;20)) significantly reduces the PFS compared with standard-risk patients. Moreover, patients cumulating several criteria had an even worse prognosis. Among SR patients according to the genomic definition with normal creatinine, median PFS of those with high beta2-microglobulin was not significantly different from patients with normal beta2-microglobulin level. This study validates the IMS/IMWG genomic definition of high-risk myeloma in a large cohort of patients diagnosed from 2019.
Référence
Blood. 2025 09 24;:
